Health Catalyst (NASDAQ:HCAT) Trading Down 6% – Time to Sell?

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) fell 6% on Tuesday . The company traded as low as $1.72 and last traded at $1.73. 1,439,357 shares changed hands during trading, an increase of 95% from the average session volume of 736,701 shares. The stock had previously closed at $1.84.

Analyst Ratings Changes

HCAT has been the topic of several recent analyst reports. UBS Group reaffirmed an “outperform” rating on shares of Health Catalyst in a report on Tuesday, November 11th. Stifel Nicolaus cut their target price on shares of Health Catalyst from $4.50 to $3.75 and set a “hold” rating on the stock in a research note on Tuesday, November 11th. William Blair reiterated an “outperform” rating on shares of Health Catalyst in a research note on Tuesday, November 11th. Wells Fargo & Company decreased their price objective on shares of Health Catalyst from $6.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Finally, Citigroup dropped their price target on Health Catalyst from $3.25 to $2.75 and set a “neutral” rating on the stock in a research report on Friday, January 9th. Five analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $4.32.

Health Catalyst Trading Down 6.0%

The business’s 50 day moving average price is $2.28 and its two-hundred day moving average price is $2.74. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.88 and a current ratio of 1.88. The company has a market capitalization of $122.36 million, a price-to-earnings ratio of -1.09 and a beta of 1.73.

Insiders Place Their Bets

In other news, Director Julie Larson-Green sold 47,997 shares of the company’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $2.67, for a total value of $128,151.99. Following the completion of the sale, the director owned 73,573 shares in the company, valued at $196,439.91. This represents a 39.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel Benjamin Landry sold 27,425 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $2.64, for a total value of $72,402.00. Following the transaction, the general counsel directly owned 100,000 shares of the company’s stock, valued at $264,000. This represents a 21.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

Institutional investors and hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Health Catalyst by 7.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 36,047 shares of the company’s stock valued at $163,000 after buying an additional 2,624 shares during the last quarter. Campbell & CO Investment Adviser LLC raised its position in Health Catalyst by 9.7% during the second quarter. Campbell & CO Investment Adviser LLC now owns 43,051 shares of the company’s stock valued at $162,000 after acquiring an additional 3,808 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Health Catalyst by 19.6% in the second quarter. The Manufacturers Life Insurance Company now owns 26,491 shares of the company’s stock valued at $100,000 after acquiring an additional 4,341 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Health Catalyst by 71.7% in the third quarter. BNP Paribas Financial Markets now owns 16,355 shares of the company’s stock valued at $47,000 after acquiring an additional 6,832 shares during the last quarter. Finally, Probity Advisors Inc. grew its position in Health Catalyst by 20.5% in the third quarter. Probity Advisors Inc. now owns 45,161 shares of the company’s stock worth $129,000 after acquiring an additional 7,671 shares in the last quarter. 85.00% of the stock is owned by institutional investors and hedge funds.

About Health Catalyst

Health Catalyst (NASDAQ: HCAT) is a healthcare data and analytics technology company founded in 2008 and headquartered in Salt Lake City, Utah. The company went public in 2019 and has since focused on delivering a unified data platform that helps healthcare organizations aggregate and analyze clinical, financial and operational information.

The core of Health Catalyst’s offering is the Data Operating System (DOS), a modular data management platform that integrates disparate data sources—from electronic health records to claims and patient-generated data—into a single analytics environment.